isoniazid has been researched along with novobiocin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (22.73) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 15 (68.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Babu, KS; Jeankumar, VU; Reddy, KI; Renuka, J; Shravan, M; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P | 1 |
| Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S | 1 |
| Babu, KS; Chuppala, A; Jeankumar, VU; Reddy, KI; Renuka, J; Sree, KS; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P | 1 |
| Renuka, J; Samala, G; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P | 1 |
| Kulkarni, P; Medapi, B; Medishetti, R; Renuka, J; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P | 1 |
| Medapi, B; Renuka, J; Sridevi, JP; Sriram, D; Suryadevara, P; Yogeeswari, P | 1 |
| Kulkarni, P; Meda, N; Medapi, B; Sriram, D; Yogeeswari, P | 1 |
| Janupally, R; Jeankumar, VU; Reshma, RS; Saxena, S; Sriram, D; Vats, R; Yogeeswari, P | 1 |
| Chaudhari, K; Jain, P; Patel, HM; Surana, S | 1 |
| Charrier, C; Cooper, IR; Kerr, WJ; Lindsay, DM; Maclean, J; McGarry, DH; Moyo, E; Pichowicz, M; Ratcliffe, AJ; Salisbury, AM; Savage, VJ; Smith, A; Stokes, NR; Walker, R; Warrilow, CE | 1 |
| Simmons, NA | 1 |
| Zimmerman, HJ | 1 |
| Kagan, BM; Levin, HS | 1 |
| Holmes, J; Sapeika, N; Zwarenstein, H | 1 |
| Ozawa, K; Shichijo, K; Takemura, Y; Yamada, T | 1 |
| Ahmed, W; Godbole, AA; Karthik, PV; Menon, S; Nagaraja, V | 1 |
1 review(s) available for isoniazid and novobiocin
| Article | Year |
|---|---|
Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Topics: Antitubercular Agents; Clinical Trials as Topic; DNA Gyrase; Drug Discovery; Humans; Mycobacterium tuberculosis; Topoisomerase II Inhibitors | 2016 |
21 other study(ies) available for isoniazid and novobiocin
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzofurans; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Topics: | 2014 |
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
Topics: Animals; Antitubercular Agents; Benzofurans; Benzothiazoles; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Humans; Macrophages; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Piperazines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Topics: Antitubercular Agents; DNA Gyrase; Drug Discovery; Humans; Mycobacterium smegmatis; Mycobacterium tuberculosis | 2015 |
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Topics: Animals; Anti-Bacterial Agents; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium smegmatis; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish | 2015 |
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Topics: Aminoquinolines; Antitubercular Agents; DNA Gyrase; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2015 |
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
Topics: Acridines; Animals; Antitubercular Agents; Bacterial Proteins; Cell Line; Cell Survival; Chlorobenzoates; DNA Gyrase; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Ether-A-Go-Go Potassium Channels; Gene Expression; Heart Rate; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish; Zebrafish Proteins | 2016 |
Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
Topics: Adenosine Triphosphatases; Antitubercular Agents; DNA Gyrase; Drug Discovery; Engineering; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium tuberculosis; Protein Conformation | 2016 |
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacteria; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Synergy and rifampicin.
Topics: Drug Synergism; Escherichia coli; Humans; Isoniazid; Novobiocin; Proteus vulgaris; Pseudomonas aeruginosa; Rifampin; Salmonella typhi; Salmonella typhimurium; Shigella dysenteriae; Tetracycline; Tuberculosis, Pulmonary | 1977 |
Liver disease caused by medicinal agents.
Topics: Adrenal Cortex Hormones; Analgesics; Chemical and Drug Induced Liver Injury; Cholestasis; Contraceptive Agents; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Fatty Liver; Halothane; Humans; Isoniazid; Jaundice; Liver; Liver Cirrhosis; Metabolism, Inborn Errors; Methotrexate; Methoxyflurane; Methyldopa; Necrosis; Novobiocin | 1975 |
Antimicrobial agents: pediatric dosage, routes of administration and preparation procedures for parenteral therapy.
Topics: Amphotericin B; Anti-Infective Agents; Bacitracin; Cephalothin; Chloramphenicol; Colistin; Erythromycin; Humans; Isoniazid; Kanamycin; Lincomycin; Neomycin; Nitrofurantoin; Novobiocin; Oleandomycin; Polymyxins; Streptomycin; Sulfadiazine; Sulfisoxazole; Tetracycline; Viomycin | 1968 |
Inhibitory effect of some quinoline, phthalazine, and coumarin derivatives on glucose-6-phosphate dehydrogenase in vitro.
Topics: Binding, Competitive; Chloroquine; Coumarins; Glucosephosphate Dehydrogenase; Heterocyclic Compounds; Hydralazine; Isoniazid; Novobiocin; Phenazines; Phenelzine; Phenylhydrazines; Probenecid; Pyridines; Quinacrine; Quinidine; Quinine; Quinolines; Sulfanilamides; Warfarin; Yeasts | 1973 |
Comparison of the effects of several drugs on tissue uptake of labeled thyroxine and triiodothyronine in the presence of rat plasma in vitro.
Topics: Animals; Chloroquine; Coloring Agents; Dinitrophenols; In Vitro Techniques; Isoniazid; Liver; Methylene Blue; Muscles; Novobiocin; Pituitary Gland; Quinine; Rats; Rose Bengal; Salicylates; Surface-Active Agents; Thyroxine; Triiodothyronine; Trypan Blue | 1966 |
Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerases, Type I; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Genes, Essential; Humans; Isoniazid; Microbial Sensitivity Tests; Microbial Viability; Mutation; Mycobacterium tuberculosis; Novobiocin; Oxazines; Tetracyclines; Tuberculosis; Xanthenes | 2014 |